
Annual report 2020
added 08-19-2023
ASLAN Pharmaceuticals Limited EPS Ratio 2011-2026 | ASLN
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.08 | -0.29 | -0.28 | -0.32 | -0.09 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.08 | -0.32 | -0.212 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-2.45 | $ 8.57 | -1.72 % | $ 84.7 M | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.62 | -1.09 % | $ 8.71 B | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 99.12 | 2.5 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 4.69 | 4.45 % | $ 760 M | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Cabaletta Bio
CABA
|
-2.1 | $ 3.26 | 1.87 % | $ 328 M | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 21.38 | 0.09 % | $ 999 M | ||
|
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
-0.53 | - | - | $ 25.3 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.54 | 4.76 % | $ 396 M | ||
|
Forte Biosciences
FBRX
|
-4.71 | $ 32.74 | 6.98 % | $ 424 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 3.04 | 4.11 % | $ 5 M | ||
|
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.16 | -0.84 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 25.13 | 4.19 % | $ 3.2 B | ||
|
Chimerix
CMRX
|
-0.93 | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
-2.33 | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
-3.9 | $ 33.21 | 1.9 % | $ 2.21 B | ||
|
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.49 | 1.36 % | $ 397 M | ||
|
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
-26.8 | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
CNS Pharmaceuticals
CNSP
|
-35.8 | $ 2.61 | 7.19 % | $ 1.16 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
CTI BioPharma Corp.
CTIC
|
-0.81 | - | - | $ 1.2 B | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M |